ZURICH 18 DECEMBER 2022. Apricot Therapeutics signed its first proof-of-concept partnership agreement to generate a unique dataset for the characterization of novel compounds that target previously thought undruggable proteins involved in cancer.
Category: IP
Options agreement with UZH
ZURICH 04 October 2022: Apricot Therapeutics AG signed an options agreement with the University of Zurich to evaluate patents rights for two patent applications based on research from the group of Lucas Pelkmans.